Cientistas of Universidade of Oxford develop a vaccine against Ebola Bundibugyo that could be available for clinical trials within two to three months. The vaccine uses ChAdOx1 technology, the same used against Covid-19, which is quickly adaptable to combat different infections. The current outbreak, concentrated in República Democrática and Congo, records 750 suspected cases and 177 deaths to date.
The Bundibugyo species, for which there is no proven vaccine, kills around a third of those infected. Organização Mundial of Saúde raised the risk of the outbreak from “high” to “very high” in República Democrática of Congo and declared a public health emergency of international concern. Testes in animals is already underway in Oxford as a preparatory step for human clinical studies.
Como works vaccine technology
The vaccine developed by Oxford uses a common cold virus that normally infects chimpanzees, genetically modified to be safe for humans. The modified virus carries genetic code from the Bundibugyo species of Ebola into cells, instructing them to recognize and fight the real disease. The vaccine does not cause infection or symptoms of Ebola, but it trains the immune system to provide protection against the virus.
ChAdOx1 technology has proven to be highly tunable during the Covid-19 pandemic. Naquela was loaded with genetic code from the Covid virus. The platform’s rapid adaptability allowed researchers to redesign the solution for Bundibugyo in a relatively short time. Essa flexibility represents a significant advantage in health emergency scenarios.
Cronograma and challenges
Não there are guarantees that the vaccine will prove effective, requiring additional research with animals and human testing. The WHO stated that there is still no animal data proving the effectiveness of this particular vaccine against Bundibugyo. A spokesperson for the organization highlighted that “it is possible that doses of this vaccine will be available for clinical trials in two or three months, but there is a lot of uncertainty.”
An alternative experimental vaccine is also in development, but it is expected to take six to nine months for any dose to be ready for testing. Professor Lambe, Calleva Head of Vaccine Immunology at Oxford Vaccine Group, emphasizes that speed is crucial: “People are worried about this outbreak, generally you prepare for the worst case scenario – hopefully contact tracing and quarantine are all that’s needed, but we can’t let our guard down.”
Mass Produção already planned
Índia’s Instituto Serum is prepared to mass produce the Ebola vaccine as soon as Oxford provides medical grade material. Segundo Lambe, “once we have the initial material, they can move forward quickly and on a large scale.” Essa partnership allows for accelerated global distribution if the vaccine demonstrates efficacy in clinical trials.
Contexto Outbreak and Bundibugyo History
Bundibugyo is one of six known Ebola virus species, but only three cause large outbreaks in humans. Esta species caused only two previous outbreaks: in Uganda, in 2007, and in República Democrática of Congo, in 2012, having not been detected for more than a decade. Existe is a proven vaccine against Ebola for the more common Zaire species, but nothing similar to Bundibugyo.
The current outbreak is mainly concentrated in Ituri province, including the cities of Mongwalu, Rwampara, Nyakunde, and Bunia. Casos were also confirmed in Uganda, in travelers originating from República Democrática of Congo. The rare nature of this species and the prior absence of vaccine tools make this outbreak particularly challenging for public health authorities.
Ring Vaccination Estratégia
Vaccines against Ebola would not be used en masse as during the Covid-19 pandemic. Instead, the ring vaccination technique is used, in which only people most likely to be infected are immunized:
- Contactos close to confirmed Ebola cases
- Profissionais healthcare treating infected patients
- Familiares of sick people
- Field Pessoal involved in contact tracing
- Laboratórios handling virus samples
Esta approach concentrates resources where the risk is greatest and reduces the need for available doses in the initial phase of implementation. Scientists are working urgently, considering the possibility that the outbreak will worsen and an experimental vaccine will soon become necessary.